Document is current
Any future updates will be listed below
-
Authors
David, Eden
Shokrian, Neda
Del Duca, Ester
Meariman, Marguerite
Glickman, Jacob
Ghalili, Sabrina
Jung, Seungyeon
Tan, Kathryn
Ungar, Benjamin
Guttman-Yassky, Emma
- License Information
-
More Information
Article History
Received: 5 May 2024
Revised: 5 July 2024
Accepted: 6 July 2024
First Online: 23 July 2024
Declarations
:
: BU is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Incyte, Rapt Therapeutics, and Pfizer. He is also a consultant for Arcutis Biotherapeutics, Bristol Myers Squib, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, and UCB. EGY is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Abbvie, Amgen, Asana BioSciences, AstraZeneca, Akari, AnaptysBio, Boehringer-Ingelheim, Eli Lilly, Galderma, Ichnos Sciences, Innovaderm Research, Janssen, Kiniksa, Kyowa Kirin, Leo Pharma, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sienna Biopharma, UCB, Union Therapeutics; and has been a consultant for Abbvie, Almirall, Amgen, Arena Pharmaceuticals, Asana BioSciences, AstraZeneca, Aslan Pharmaceuticals, Bristol Myers Squibb, Boehringer-Ingelheim, Cara Therapeutics, Castle Biosciences, DBV Technologies, DS Biopharma, Eli Lilly, Evommune, Galderma, Genzyme Corporation, GSK, Ichnos Sciences, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Novan, Novartis, RAPT Therapeutics, Sanofi, Sato Pharmaceutical, Siolta, Union Therapeutics, and Ventyx. The rest of the authors declare no relevant conflicts of interest.
: BU is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Incyte, Rapt Therapeutics, and Pfizer. He is also a consultant for Arcutis Biotherapeutics, Bristol Myers Squib, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, and UCB. EGY is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Abbvie, Amgen, Asana BioSciences, AstraZeneca, Akari, AnaptysBio, Boehringer-Ingelheim, Eli Lilly, Galderma, Ichnos Sciences, Innovaderm Research, Janssen, Kiniksa, Kyowa Kirin, Leo Pharma, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sienna Biopharma, UCB, Union Therapeutics; and has been a consultant for Abbvie, Almirall, Amgen, Arena Pharmaceuticals, Asana BioSciences, AstraZeneca, Aslan Pharmaceuticals, Bristol Myers Squibb, Boehringer-Ingelheim, Cara Therapeutics, Castle Biosciences, DBV Technologies, DS Biopharma, Eli Lilly, Evommune, Galderma, Genzyme Corporation, GSK, Ichnos Sciences, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Novan, Novartis, RAPT Therapeutics, Sanofi, Sato Pharmaceutical, Siolta, Union Therapeutics, and Ventyx. The rest of the authors declare no relevant conflicts of interest.
: The authors affirm that human research participants provided informed consent for publication of the images in Fig. .
